 | Lugthart_2010_JClinOncol_HOVON_July26.pdf[10.77 KB] | | |
| Lugthart S, Gröschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, Ossenkoppele GJ, Vellenga E, Eva VD, Schanz U, Verhoef G, Vandenberghe P, Ferrant A, Köhne CH, Pfreundschuh M, Horst HA, Koller E, von Lilienfeld-Toal M, Bentz M, Ganser A, Schlegelberger B, Jotterand M, Krauter J, Pabst T, Theobald M, Schlenk RF, Delwel R, Döhner K, Löwenberg B, Döhner H.Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia.J Clin Oncol. 2010 Aug 9. [Epub ahead of print] |
 |
| Rochlitz_2010_AnnOncol_SAKK24-06_Juli1.pdf[12 KB] | | |
| Rochlitz C, Ruhstaller T, Lerch S, Spirig C, Huober J, Suter T, Bühlmann M, Fehr M, Schönenberger A, von Moos R, Winterhalder R, Rauch D, Müller A, Mannhart-Harms M, Herrmann R, Cliffe B, Mayer M, Zaman K; on behalf of the Swiss Group for Clinical Cancer Research (SAKK). Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Ann Oncol. 2010 Jul 1. [Epub ahead of print] |
|
| Jost_2010_GastrointestEndosc_SAKK75-02_June.pdf[13.18 KB] | | |
| Jost C, Binek J, Schuller JC, Bauerfeind P, Metzger U, Werth B, Knuchel J, Frossard JL, Bertschinger P, Brauchli P, Meyenberger C, Ruhstaller T. Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research (SAKK 75/02). Gastrointest Endosc. 2010 Jun;71(7):1114-1121. Epub 2010 Mar 20. |
|
| Ladenstein_2010_JClinOncol_Euro-EWING-99.June14.pdf[12.42 KB] | | |
| Ladenstein R, Pötschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, van den Berg H, Dirksen U, Hjorth L, Michon J, Lewis I, Craft A, Jürgens H. Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 Trial. J Clin Oncol. 2010 Jun 14. [Epub ahead of print] |
|
| Moreau_2010_Leukemia_IFM-2005-01_June.pdf[4.71 KB] | | |
| Moreau P, Hulin C, Marit G, Caillot D, Facon T, Lenain P, Berthou C, Pégourié B, Stoppa AM, Casassus P, Michallet M, Benboubker L, Maisonneuve H, Doyen C, Leyvraz S, Mathiot C, Avet-Loiseau H, Attal M, Harousseau JL. Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial. Leukemia. 2010 Jun;24(6):1233-5. Epub 2010 Apr 29 |
|
| Taphoorn_2010_EurJCancer_EORTC QLQ-BN20.April.pdf[11.52 KB] | | |
| Taphoorn MJ, Claassens L, Aaronson NK, Coens C, Mauer M, Osoba D, Stupp R, Mirimanoff RO, van den Bent MJ, Bottomley A; EORTC Quality of Life Group, and Brain Cancer, NCIC and Radiotherapy Groups. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer. 2010 Apr;46(6):1033-40. Epub 2010 Feb 22. |
|
| VonMoos_2010_Onkologie_SAKK41-03_May14.pdf[6.99 KB] | | |
| von Moos R, Roth A, Ruhstaller T, Widmer L, Uhlmann C, Cathomas R, Köberle D, Simcock M, Lanz D, Popescu R. Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03). Onkologie. 2010;33(6):295-9. Epub 2010 May 14. |
|
| Engert_2010_JClinOncol_HD-15_May1.pdf[7.7 KB] | | |
| Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial.J Clin Oncol. 2010 May 1;28(13):2239-45. Epub 2010 Apr 5. |
|
| Ruhstaller_2010_Onkologie_sakk76-02_Apr9.pdf[7.57 KB] | | |
| Ruhstaller T, Templeton A, Ribi K, Schuller JC, Borner M, Thierstein S, von Moos R, Pederiva S, Lohri A, Lombriser N, von Briel C, Koeberle D, Popescu R. Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02).Onkologie. 2010;33(5):222-8. Epub 2010 Apr 9. |
|
| Lowenberg_2010_Blood_HOVON-43_April1.pdf[9.89 KB] | | |
| Löwenberg B, Beck J, Graux C, van Putten W, Schouten HC, Verdonck LF, Ferrant A, Sonneveld P, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, Breems D, de Muijnck H, Schaafsma MR, Verhoef G, Döhner H, Gratwohl A, Pabst T, Ossenkoppele GJ, Maertens J. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase III study. Blood. 2010 Apr 1;115(13):2586-91. Epub 2010 Jan 26. |
|
| Pagani_2010_JNatlCancerInst_ESO-MBC_March10.pdf[55.54 KB] | | |
| Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, Costa A, Winer EP, Cardoso F; on behalf of the ESO–MBC Task Force.International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?J Natl Cancer Inst. 2010 Mar 10. [Epub ahead of print] |
|
| Leupin_2010_LeukLymphoma_SAKK34-02_March10.pdf[58.07 KB] | | |
Leupin N, Schuller JC, Solenthaler M, Heim D, Rovo A, Beretta K, Gregor M, Bargetzi MJ, Brauchli P, Himmelmann A, Hanselmann S, Zenhäusern R. Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02).Leuk Lymphoma. 2010 Mar 10. [Epub ahead of print]
|
|
| Koeberle_2010_Oncologist_SAKK77-06_March4.pdf[60.45 KB] | | |
| Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovàcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G.Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06).Oncologist. 2010 Mar 4. [Epub ahead of print] |
|
| Barlogie_2010_JClinOncol_IFM90-IFM04-IFM9902-IFM9904_March1.pdf[56.54 KB] | | |
| Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J Clin Oncol. 2010 Mar 1;28(7):1209-14. Epub 2010 Jan 19. |
|
| Paridaens_2010_BreastCancerResTreat_IBCSG11-93_Feb27.pdf[58.9 KB] | | |
| Paridaens RJ, Gelber S, Cole BF, Gelber RD, Thürlimann B, Price KN, Holmberg SB, Crivellari D, Coates AS, Goldhirsch A. Adjuvant!((c)) Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat. 2010 Feb 27. [Epub ahead of print] |
|
| Ess_2010_CancerEpidemiol_CancerRegistry_Feb23.pdf[53.47 KB] | | |
| Ess S, Savidan A, Frick H, Rageth C, Vlastos G, Lütolf U, Thürlimann B. Geographic variation in breast cancer care in Switzerland. Cancer Epidemiol. 2010 Feb 23. [Epub ahead of print] |
|
| Antonov_2010_BMCCancer_BIG1-98_Feb8.pdf[59.92 KB] | | |
| Antonov J, Popovici V, Delorenzi M, Wirapati P, Baltzer A, Oberli A, Thurlimann B, Giobbie-Hurder A, Viale G, Altermatt HJ, Aebi S, Jaggi R. Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue. BMC Cancer. 2010 Feb 9;10(1):37. [Epub ahead of print] |
|
| Biffi_2010_WorldJGastroenterol_SAKK43-99_Feb21.pdf[56.11 KB] | | |
Biffi R, Fazio N, Luca F, Chiappa A, Andreoni B, Zampino MG, Roth A, Schuller JC, Fiori G, Orsi F, Bonomo G, Crosta C, Huber O. Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer.
World J Gastroenterol. 2010 Feb 21;16(7):868-74. |
|
| Roth_2010_JClinOncol_SAKK60-00_Jan20.pdf[61.21 KB] | | |
| Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F. Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial. J Clin Oncol. 2010 Jan 20;28(3):466-74. Epub 2009 Dec 14. |
|
| Roussel_2010_Blood_IFM-2005 01_Jan7.pdf[58.19 KB] | | |
| Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J Clin Oncol. 2010 Jan 19. [Epub ahead of print] |
|
| Arriagada_2010_JClinOncol_IALT_abstract_Jan1.pdf[57.07 KB] | | |
| Arriagada R, Dunant A, Pignon JP, Bergman B, Chabowski M, Grunenwald D, Kozlowski M, Le Péchoux C, Pirker R, Pinel MI, Tarayre M, Le Chevalier T. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010 Jan 1;28(1):35-42. |
